Shopping Cart
Remove All
Your shopping cart is currently empty
Olanzapine (LY170053) is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $30 | In Stock | In Stock | |
| 50 mg | $39 | In Stock | In Stock | |
| 100 mg | $55 | In Stock | In Stock | |
| 500 mg | $123 | In Stock | In Stock | |
| 1 g | $179 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $43 | In Stock | In Stock |
| Description | Olanzapine (LY170053) is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. |
| Targets&IC50 | α1-adrenoceptor:19 nM (Ki), 5-HT1 receptor:7 nM (Ki), 5-HT2C receptor:11 nM (Ki), Muscarinic M1-5 Receptor:1.9-25 nM (Ki), 5-HT3 receptor:57 nM (Ki), 5-HT6 receptor:5 nM (Ki), 5-HT2A receptor:4 nM (Ki) |
| In vitro | Olanzapine is a potent antagonist of DA and 5-HT receptors, which elevates the extracellular levels of DA metabolites, such as DOPAC, and the DA metabolite 3-methoxytyramine, in the prefrontal cortex, nucleus accumbens, and striatum of rats. Subcutaneous injections of Olanzapine (0.5-10 mg/kg) increase the levels of dopamine (DA) and norepinephrine (NE) in these regions in a dose-dependent manner. Additionally, Olanzapine significantly inhibits insulin, leading to the onset of obesity. |
| In vivo | Olanzapine interacts with several key receptors associated with schizophrenia, demonstrating nanomolar affinity for dopamine, serotonin, alpha-1 adrenergic, and cholinergic receptors. Specifically, Olanzapine selectively targets striatal dopamine in the limbic and cortical regions of the brain, exhibiting no selectivity towards dopamine receptor subtypes. |
| Synonyms | LY170053 |
| Molecular Weight | 312.43 |
| Formula | C17H20N4S |
| Cas No. | 132539-06-1 |
| Smiles | CN1CCN(CC1)C1=NC2=C(NC3=C1C=C(C)S3)C=CC=C2 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (768.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (16 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.